Keyword Analysis & Research: kcentra uptodate
Keyword Research: People who searched kcentra uptodate also searched
Search Results related to kcentra uptodate on Search Engine
-
Reversal of anticoagulation in intracranial hemorrhage - UpToDate
https://www.uptodate.com/contents/reversal-of-anticoagulation-in-intracranial-hemorrhage
WEBFeb 26, 2024 · Reversal of anticoagulation in patients with anticoagulant-associated intracranial hemorrhage is a medical emergency, as anticoagulation is associated with greater hematoma growth, neurologic deterioration, and increased risk of death and major disability compared with no anticoagulation.
DA: 66 PA: 91 MOZ Rank: 10
-
Management of warfarin-associated bleeding or ... - UpToDate
https://www.uptodate.com/contents/management-of-warfarin-associated-bleeding-or-supratherapeutic-inr
WEBSep 29, 2023 · This topic last updated: Sep 29, 2023. INTRODUCTION. Warfarin is associated with an increased risk of bleeding, as are a variety of other anticoagulants. The effect of warfarin has great inter- and intra-individual variation based on a variety of genetic, dietary, and medication effects.
DA: 12 PA: 52 MOZ Rank: 48
-
Approach to acute upper gastrointestinal bleeding in adults - UpToDate
https://www.uptodate.com/contents/approach-to-acute-upper-gastrointestinal-bleeding-in-adults/print
WEBMar 15, 2023 · Approach to acute upper gastrointestinal bleeding in adults. Author: John R Saltzman, MD, FACP, FACG, FASGE, AGAF. Section Editor: Mark Feldman, MD, MACP, AGAF, FACG. Deputy Editor: Anne C Travis, MD, MSc, FACG, AGAF. Literature review current through: Feb 2024. This topic last updated: Mar 15, 2023.
DA: 98 PA: 47 MOZ Rank: 91
-
DOAC reversal agents for life-threatening bleeding - UpToDate
https://sso.uptodate.com/contents/image?imageKey=HEME/112299&topicKey=SURG%2F1383&source=outline_link
WEB4-factor PCC (Kcentra, Beriplex P/N, Octaplex). Dosing can be done with a fixed dose of 2000 units OR a weight-based dose of 25 to 50 units per kg. Reversal agents carry a risk of life-threatening thrombosis and should only be used under the direction of a specialist with expertise in their use and/or in a patient at imminent risk of death from ...
DA: 71 PA: 26 MOZ Rank: 48
-
Anticoagulation Reversal Guideline for Adults - American …
https://www.heart.org/-/media/files/professional/quality-improvement/hemorrhagic--stroke/hemorrhagic-stroke-toolkit-page/5_18_2021/anticoagulation-reversal-guideline-for-adults-5182021.pdf?la=en
WEBKcentra® (use actual body weight): INR <1.4: Not recommended INR 1.4-2.0: Use clinical judgment INR 2.0-3.9: 25 units/kg (2500 units max) INR 4.0-6.0: 35 units/kg (3500 units max) INR >6.0: 50 units/kg (5000 units max) FEIBA® should be given if the patient has a history of HIT (same dosing as Kcentra®)
DA: 64 PA: 30 MOZ Rank: 11
-
Indications, Efficacy and Complications of Kcentra Use in …
https://ashpublications.org/blood/article/132/Supplement%201/3820/264963/Indications-Efficacy-and-Complications-of-Kcentra
WEBNov 29, 2018 · In this study we examine the indications for administration of Kcentra, efficacy of the PCC in several coagulopathies, incidence of adverse events including ischemic stroke and DVT/ PE, and overall mortality.
DA: 69 PA: 49 MOZ Rank: 19
-
Anticoagulant Reversal in Gastrointestinal Bleeding: Review of
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245141/
WEBIt is important to keep these approval dates in mind when evaluating guidelines published during this period. In general, guidelines suggest that anticoagulant reversal should be considered in patients with clinically significant GI bleeding and an INR > 2.5, with PCC considered a first-line option for reversal.
DA: 98 PA: 86 MOZ Rank: 9
-
Clinical experience reversing factor Xa inhibitors with four …
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034772/
WEBIntroduction. In 2013, the United States Food and Drug Administration (FDA) approved Kcentra ® (CSL Behring GmbH, Kankakee, IL, USA), for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (e.g. warfarin) in adult patients with acute major bleeding or need for urgent surgery/invasive procedure. This four …
DA: 76 PA: 83 MOZ Rank: 45
-
The Use of Kcentra ® in the Reversal of Coagulopathy of ... - PubMed
https://pubmed.ncbi.nlm.nih.gov/29278982/
WEBPMID: 29278982. DOI: 10.1177/0897190017696952. Abstract. We aim to describe our experience with the four-factor prothrombin complex concentrates (4F-PCC) Kcentra ® at differing doses in patients with liver cirrhosis requiring emergent hemostasis in the setting of major or life-threatening bleeding.
DA: 87 PA: 67 MOZ Rank: 81
-
Reversal of Newer Anticoagulants in Acute Hemorrhagic Stroke
https://www.uspharmacist.com/article/reversal-of-newer-anticoagulants-in-acute-hemorrhagic-stroke
WEBJan 22, 2014 · Despite the lack of definitive data, a few things are certain. First, discontinuation of the OAC is paramount. The use of hemodialysis in patients receiving dabigatran is also an option. Four-factor PPCs, such as Kcentra, seem to be the most promising emergent treatment.
DA: 32 PA: 25 MOZ Rank: 83
